Growth factor receptor kinase inhibitors: Recent progress and clinical impact

Current Opinion in Drug Discovery and Development

Volumn 4, Issue 4, 2001, Pages 378-389

  Dumas, J ^a  

^a BAYER CORPORATION   (United States)

Author keywords

Angiogenesis; c kit; Cancer; EGFR; ErbB 2; FGFR; Growth factor receptor tyrosine kinase; PDGFR; Restenosis; VEGFR

Indexed keywords

2 AMINO 7 (3 TERT BUTYLUREIDO) 6 (2,6 DICHLOROPHENYL)PYRIDO[2,3 D]PYRIMIDINE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ADL 681; AG 13764; AG 13925; CANERTINIB; CGP 59326; CGP 75166; CL 387785; CT 052923; EKI 785; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GW 2286; IMATINIB; LAPATINIB; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; NVP AAD777; PD 166285; PD 166866; PD 169414; PD 173074; PELITINIB; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR INHIBITOR; RPR 101511; RPR 10151A; RPR 127963; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VATALANIB; WO 09917769;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACTIVITY; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; REVIEW;

ANIMALS; ENZYME INHIBITORS; HUMANS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR;

EID: 0034915963     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Tyrosine kinase inhibitors in cancer treatment (Part II)
2. Current progress towards the development of tyrosine kinase inhibitors as anticancer agents
3. ATP site-directed competitive and irreversible inhibitors of protein kinases
4. Protein kinase inhibitors: Emerging pharmacophores (1997-2000)
5. Selective tyrosine kinase inhibitors
6. The epidermal growth factor receptor and its inhibition in cancer therapy
7. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy
8. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
9. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases
10. ZD1839 ('Iressa') as an anticancer agent
11. ZD1839 ('Iressa'), a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): Correlation of c-fos expression and tumor growth inhibition
12. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), and epidermal growth factor receptor-selective tyrosine kinase inhibitor
13. ZD1839 ('Iressa'), an oral EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor): Pharmacokinetic results of a phase I study in patients with advanced cancer
14. A phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in Japanese patients with solid malignant tumors
15. A phase I, dose-escalation, pharmacokinetic (PK) and pharmacodynamic (PD) study of ZD1839 ('Iressa'): NCIC-CTG IND. 122
16. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
17. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice
18. A phase II, multi-center study of the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI), CP-358774, in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN)
19. A phase II trial of the epidermal growth factor (EGFR) tyrosine kinase inhibitor (TKI), CP-358,774, following platinum-based chemotherapy in patients (pts) with advanced non-small cell lung cancer
20. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions
21. Preclinical profile of PKI-166 a novel and potent EGFR tyrosine kinase inhibitor for clinical development
22. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
23. Pharmacokinetic/pharmacodynamic profile of the EGF-receptor inhibitor PKI166 in nude mice bearing NCI H-596 lung tumor xenografts
24. The discovery of a new anti-cancer agent GW2016: A potent, dual EGFR/ErbB-2 tyrosine kinase inhibitor
25. Anti-tumor activity of GW2016 in the EGFR positive HN5 human head and neck cancer xenograff
26. Inhibitors of tyrosine kinases in the treatment of psoriasis
27. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)
28. In vitro modulation of cyst formation by a novel tyrosine kinase inhibitor
29. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor
30. Combinatorial chemoprevention of intestinal neoplasia
31. EKB-569: A new irreversible inhibitor of epidermal growth factor receptor tyrosine kinase for the treatment of cancer
32. A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo
33. A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo
34. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methyl-amino-substituted derivatives of 4-(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors
35. Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD-0169414 against human tumor xenografts
36. Cancer chemotherapeutics - Angiogenesis agents: October 1999 - March 2000
37. VEGF receptor signaling in tumor angiogenesis
38. Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases
39. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (FIk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
40. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function
41. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
42. ZD6474: Design, synthesis and structure-activity relationship of a novel, orally active VEGF receptor tyrosine kinase inhibitor
43. Pharmacological efficacy of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in rat
44. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis
45. PTK787/ZK-222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
46. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors
47. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy
48. An orally active inhibitor of VEGF receptor tyrosine kinase with potent anti-tumor activity
49. NVP-ADD777/ZK202664, a selective VEGF receptor kinase inhibitor, which inhibits both VEGF- and bFGF-induced angiogenesis
50. Potent in vitro inhibition of VEGF-mediated endothelial cell survival and KDR signaling by AG13764, a novel small molecule inhibitor of the VEGF tyrosine kinase receptors
51. Inhibition of angiogenesis and tumor growth by AG13925, a small molecule inhibitor of vascular endothelial growth factor receptor tyrosine kinase
52. New structural class of KDR kinase inhibitors: Initial SAR of the screening lead
53. Advancement of a novel class of KDR kinase inhibitors: Optimization of potency and physical properties
54. Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR
55. Platelet-derived growth factor receptor signals
56. Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A
57. Tyrosine kinase inhibitors
58. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl) methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases
59. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
60. SU6668, a broad spectrum angiogenesis inhibitor is active in diverse models of tumor growth and metastasis
61. Phase I experience with oral SU6668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies
62. STI-751 Novartis AG
63. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
64. Potent and selective inhibitors of the Abl-kinase: Phenylamino-pyrimidine (PAP) derivatives
65. Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo
66. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: Identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors
67. Structure-activity relationships for 1-phenyl-benzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor
68. Structure-activity relationships for 5-substituted 1-phenylbenzimidazoles as selective inhibitors of the platelet-derived growth factor receptor
69. Selective orally active platelet-derived growth factor receptor (PDGFR) antagonists prevent autocrine-mediated tumor growth in nude mice
70. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors
71. In vitro biological characterization and antiangiogenic effects of PD-166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase
72. 3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase
73. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
74. The FGFR1 inhibitor PD-173074 selectively and potently antagonizes FGF-2 neutrotrophic and neurotropic effects
75. In vitro pharmacological characterization of PD-166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor
76. Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: Implications for combination treatment with photodynamic therapy
77. The biology of stem cell factor and its receptor C-kit
78. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI-571
79. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
80. Inhibition of c-kit receptor tyrosine kinase activity by STI-571, a selective tyrosine kinase inhibitor
81. The tyrosine kinase inhibitor SU5416 reduces proliferation and colony-formation of primary AML blasts after co-culture with a newly derived endothelial feeder cell line